1-Deamino-8-d-arginine vasopressin (DDAVP): a potential new treatment for the bleeding diathesis of acute renal failure.
The treatment of the haemorrhagic tendency of acute renal failure remains unsatisfactory. To investigate a potential new therapy, 8 patients with acute renal failure and prolonged bleeding times received an infusion of 1-deamino-8-d-arginine vasopressin (0.4 microgram/kg). This resulted in significant shortening of the bleeding time at 1 and 2 hours post-infusion. The beneficial effect on bleeding time had largely disappeared by 8 hours. Pre-infusion Factor VIII activities were either within the normal range or mildly increased and a tendency to further elevation was noted post-DDAVP. In contrast, no alteration in platelet count or haematocrit was observed. No adverse effects were reported, and no significant change in heart rate, blood pressure or plasma osmolarity was noted.
D058186:Acute Kidney Injury / Q000150:complications*; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D001760:Bleeding Time; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D005167:Factor VII / Q000378:metabolism; D005260:Female; D006474:Hemorrhagic Disorders / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D010979:Platelet Function Tests; D013997:Time Factors
D001127:Arginine Vasopressin; D005167:Factor VII; D003894:Deamino Arginine Vasopressin